Return to the full list of Biomarkers
Eye Tracking in Reading (ADAL)
Method of Measurement (Pre-analytical Tools)
Optical
Biomarker Measured
Eye movement
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results
Identify early and accurate markers of AD by associating semantic neuropsychological assessments and eye tracking during sentences reading.
Target Population/ Population Being Studied
People with Alzheimer's disease or related disorders and age matched controls
Length of Current Trial
6 months
Number of Trial Participants
48
Estimated Trial Completion
11/1/2017 Clinical trials says this is active, but the end date has passed
What is Required from Patients
noninvasive eye tracking test, in clinic visit
What is Required from the Health System
eye tracking device
Sponsor
Centre Hospitalier Universitaire de Nice
“Identification of Early Markers of Alzheimer's Disease by Using Eye Tracking in Reading. (ADAL).”ClinicalTrials.gov. Accessed October 10, 2019.
https://clinicaltrials.gov/ct2/show/NCT02557464?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=2&rank=16